Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles

For influenza virus, we developed an efficient, noncytotoxic, plasmid-based virus-like particle (VLP) system to reflect authentic virus particles. This system was characterized biochemically by analysis of VLP protein composition, morphologically by electron microscopy, and functionally with a VLP i...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of virology Vol. 81; no. 13; p. 7111
Main Authors:	Chen, Benjamin J, Leser, George P, Morita, Eiji, Lamb, Robert A
Format:	Journal Article
Language:	English
Published:	United States 01.07.2007
Subjects:	Animals Cercopithecus aethiops COS Cells DNA-Directed RNA Polymerases Gene Expression HeLa Cells Hemagglutinin Glycoproteins, Influenza Virus - genetics Hemagglutinin Glycoproteins, Influenza Virus - metabolism Humans Influenza A Virus, H3N2 Subtype - physiology Influenza A Virus, H3N2 Subtype - ultrastructure Models, Biological Neuraminidase - genetics Neuraminidase - metabolism Plasmids - genetics Plasmids - metabolism Vaccinia virus Vero Cells Viral Matrix Proteins - genetics Viral Matrix Proteins - metabolism Viral Proteins Virus Assembly - physiology
ISSN:	0022-538X
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	For influenza virus, we developed an efficient, noncytotoxic, plasmid-based virus-like particle (VLP) system to reflect authentic virus particles. This system was characterized biochemically by analysis of VLP protein composition, morphologically by electron microscopy, and functionally with a VLP infectivity assay. The VLP system was used to address the identity of the minimal set of viral proteins required for budding. Combinations of viral proteins were expressed in cells, and the polypeptide composition of the particles released into the culture media was analyzed. Contrary to previous findings in which matrix (M1) protein was considered to be the driving force of budding because M1 was found to be released copiously into the culture medium when M1 was expressed by using the vaccinia virus T7 RNA polymerase-driven overexpression system, in our noncytotoxic VLP system M1 was not released efficiently into the culture medium. Additionally, hemagglutinin (HA), when treated with exogenous neuraminidase (NA) or coexpressed with viral NA, could be released from cells independently of M1. Incorporation of M1 into VLPs required HA expression, although when M1 was omitted from VLPs, particles with morphologies similar to those of wild-type VLPs or viruses were observed. Furthermore, when HA and NA cytoplasmic tail mutants were included in the VLPs, M1 failed to be efficiently incorporated into VLPs, consistent with a model in which the glycoproteins control virus budding by sorting to lipid raft microdomains and recruiting the internal viral core components. VLP formation also occurred independently of the function of Vps4 in the multivesicular body pathway, as dominant-negative Vps4 proteins failed to inhibit influenza VLP budding.
AbstractList	For influenza virus, we developed an efficient, noncytotoxic, plasmid-based virus-like particle (VLP) system to reflect authentic virus particles. This system was characterized biochemically by analysis of VLP protein composition, morphologically by electron microscopy, and functionally with a VLP infectivity assay. The VLP system was used to address the identity of the minimal set of viral proteins required for budding. Combinations of viral proteins were expressed in cells, and the polypeptide composition of the particles released into the culture media was analyzed. Contrary to previous findings in which matrix (M1) protein was considered to be the driving force of budding because M1 was found to be released copiously into the culture medium when M1 was expressed by using the vaccinia virus T7 RNA polymerase-driven overexpression system, in our noncytotoxic VLP system M1 was not released efficiently into the culture medium. Additionally, hemagglutinin (HA), when treated with exogenous neuraminidase (NA) or coexpressed with viral NA, could be released from cells independently of M1. Incorporation of M1 into VLPs required HA expression, although when M1 was omitted from VLPs, particles with morphologies similar to those of wild-type VLPs or viruses were observed. Furthermore, when HA and NA cytoplasmic tail mutants were included in the VLPs, M1 failed to be efficiently incorporated into VLPs, consistent with a model in which the glycoproteins control virus budding by sorting to lipid raft microdomains and recruiting the internal viral core components. VLP formation also occurred independently of the function of Vps4 in the multivesicular body pathway, as dominant-negative Vps4 proteins failed to inhibit influenza VLP budding. For influenza virus, we developed an efficient, noncytotoxic, plasmid-based virus-like particle (VLP) system to reflect authentic virus particles. This system was characterized biochemically by analysis of VLP protein composition, morphologically by electron microscopy, and functionally with a VLP infectivity assay. The VLP system was used to address the identity of the minimal set of viral proteins required for budding. Combinations of viral proteins were expressed in cells, and the polypeptide composition of the particles released into the culture media was analyzed. Contrary to previous findings in which matrix (M1) protein was considered to be the driving force of budding because M1 was found to be released copiously into the culture medium when M1 was expressed by using the vaccinia virus T7 RNA polymerase-driven overexpression system, in our noncytotoxic VLP system M1 was not released efficiently into the culture medium. Additionally, hemagglutinin (HA), when treated with exogenous neuraminidase (NA) or coexpressed with viral NA, could be released from cells independently of M1. Incorporation of M1 into VLPs required HA expression, although when M1 was omitted from VLPs, particles with morphologies similar to those of wild-type VLPs or viruses were observed. Furthermore, when HA and NA cytoplasmic tail mutants were included in the VLPs, M1 failed to be efficiently incorporated into VLPs, consistent with a model in which the glycoproteins control virus budding by sorting to lipid raft microdomains and recruiting the internal viral core components. VLP formation also occurred independently of the function of Vps4 in the multivesicular body pathway, as dominant-negative Vps4 proteins failed to inhibit influenza VLP budding.For influenza virus, we developed an efficient, noncytotoxic, plasmid-based virus-like particle (VLP) system to reflect authentic virus particles. This system was characterized biochemically by analysis of VLP protein composition, morphologically by electron microscopy, and functionally with a VLP infectivity assay. The VLP system was used to address the identity of the minimal set of viral proteins required for budding. Combinations of viral proteins were expressed in cells, and the polypeptide composition of the particles released into the culture media was analyzed. Contrary to previous findings in which matrix (M1) protein was considered to be the driving force of budding because M1 was found to be released copiously into the culture medium when M1 was expressed by using the vaccinia virus T7 RNA polymerase-driven overexpression system, in our noncytotoxic VLP system M1 was not released efficiently into the culture medium. Additionally, hemagglutinin (HA), when treated with exogenous neuraminidase (NA) or coexpressed with viral NA, could be released from cells independently of M1. Incorporation of M1 into VLPs required HA expression, although when M1 was omitted from VLPs, particles with morphologies similar to those of wild-type VLPs or viruses were observed. Furthermore, when HA and NA cytoplasmic tail mutants were included in the VLPs, M1 failed to be efficiently incorporated into VLPs, consistent with a model in which the glycoproteins control virus budding by sorting to lipid raft microdomains and recruiting the internal viral core components. VLP formation also occurred independently of the function of Vps4 in the multivesicular body pathway, as dominant-negative Vps4 proteins failed to inhibit influenza VLP budding.
Author	Morita, Eiji Chen, Benjamin J Leser, George P Lamb, Robert A
Author_xml	– sequence: 1 givenname: Benjamin J surname: Chen fullname: Chen, Benjamin J organization: Department of Biochemistry, Molecular Biology and Cell Biology, Northwestern University, Evanston, IL 60208-3500, USA – sequence: 2 givenname: George P surname: Leser fullname: Leser, George P – sequence: 3 givenname: Eiji surname: Morita fullname: Morita, Eiji – sequence: 4 givenname: Robert A surname: Lamb fullname: Lamb, Robert A
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/17475660$$D View this record in MEDLINE/PubMed
BookMark	eNo1kD1PwzAYhD2AoAU2ZuSJqSl24sTJiCo-iiqxAGKr3sRvWoPjtP6ogJ_CryWCMp1OenSnuzE5sL1FQs45m3KellcPL_MpY1nBEyYPyIixNE3yrHw9JmPv3xjjQhTiiBxzKWReFGxEvue2NRHtF9CddtHTNXawWpkYtNWWglXUYnTQDVaBxwmtY6C2DzSskXYQnP6gG9cH1HZCwSF1uI3aoaJt7yh4j11tPn-D6qiUtivat3RjwHdaJQqd3g3sb3di9DvSDbigG4P-lBy2YDye7fWEPN_ePM3uk8Xj3Xx2vUgaIVlI2pRxpirRNpI3VSnzUmSywiJLBeSMtxUvGLYVQKOAV7yskcsmLXOeQV5nUqQn5PIvd5ixjejDstO-QWPAYh_9UrKCZ6ziA3ixB2PdoVpunO7AfS7_30x_AGUJeSc
CitedBy_id	crossref_primary_10_1128_JVI_05681_11 crossref_primary_10_1016_j_virol_2008_08_010 crossref_primary_10_1586_erv_09_8 crossref_primary_10_1038_s41467_024_50162_x crossref_primary_10_1111_j_1467_7652_2009_00496_x crossref_primary_10_1016_j_vetmic_2012_11_035 crossref_primary_10_1111_j_1467_7652_2008_00384_x crossref_primary_10_1007_s12250_012_3241_1 crossref_primary_10_1002_bit_25159 crossref_primary_10_1016_j_jaerosci_2025_106673 crossref_primary_10_3389_fmicb_2024_1355599 crossref_primary_10_1038_ncomms3763 crossref_primary_10_1186_s13567_020_00879_6 crossref_primary_10_1099_vir_0_038778_0 crossref_primary_10_1016_j_vaccine_2010_08_040 crossref_primary_10_3390_v12070780 crossref_primary_10_1111_j_1462_5822_2009_01286_x crossref_primary_10_1186_1743_422X_10_141 crossref_primary_10_1016_j_bpj_2021_11_023 crossref_primary_10_1139_w2012_006 crossref_primary_10_1111_irv_12274 crossref_primary_10_1371_journal_pone_0018780 crossref_primary_10_1186_s12896_025_01016_x crossref_primary_10_1007_BF03256169 crossref_primary_10_1128_JVI_01885_10 crossref_primary_10_1128_JVI_00307_10 crossref_primary_10_1016_j_chom_2017_10_003 crossref_primary_10_1042_BST20200854 crossref_primary_10_1371_journal_pone_0082431 crossref_primary_10_3390_v3010026 crossref_primary_10_1016_j_vaccine_2012_10_083 crossref_primary_10_1128_JVI_00759_21 crossref_primary_10_1080_14760584_2018_1516552 crossref_primary_10_1016_j_jbiotec_2020_03_013 crossref_primary_10_1128_JVI_00514_08 crossref_primary_10_1080_03079450802357001 crossref_primary_10_1128_JVI_02104_16 crossref_primary_10_1016_j_vaccine_2017_06_024 crossref_primary_10_1128_jvi_01398_23 crossref_primary_10_1146_annurev_cellbio_101011_155838 crossref_primary_10_1128_JVI_01479_12 crossref_primary_10_1002_rmv_1872 crossref_primary_10_1073_pnas_1012199108 crossref_primary_10_1007_s10858_016_0025_1 crossref_primary_10_1111_cmi_12045 crossref_primary_10_1128_CVI_00153_12 crossref_primary_10_1128_JVI_01667_08 crossref_primary_10_1016_j_vaccine_2008_11_011 crossref_primary_10_1017_S1466252310000137 crossref_primary_10_1042_BC20090161 crossref_primary_10_1128_JVI_01491_08 crossref_primary_10_1074_jbc_M112_412726 crossref_primary_10_1371_journal_pone_0021123 crossref_primary_10_1016_j_vaccine_2012_10_065 crossref_primary_10_1063_5_0071515 crossref_primary_10_1016_j_jviromet_2009_10_020 crossref_primary_10_1042_BST20120166 crossref_primary_10_1016_j_abb_2015_04_011 crossref_primary_10_1186_s12896_015_0152_x crossref_primary_10_1002_1873_3468_12118 crossref_primary_10_1016_j_virol_2013_01_001 crossref_primary_10_1186_s12985_024_02295_0 crossref_primary_10_1080_08830185_2018_1500570 crossref_primary_10_1016_j_ijbiomac_2022_01_108 crossref_primary_10_1016_j_jbc_2022_101727 crossref_primary_10_1128_jvi_01563_23 crossref_primary_10_1371_journal_pone_0037786 crossref_primary_10_1128_JVI_07158_11 crossref_primary_10_1371_journal_pone_0242452 crossref_primary_10_1016_j_bpj_2010_12_3701 crossref_primary_10_1016_j_virol_2019_03_004 crossref_primary_10_1371_journal_pone_0288970 crossref_primary_10_1128_JVI_00421_09 crossref_primary_10_1002_mabi_202400088 crossref_primary_10_1038_nmicrobiol_2016_50 crossref_primary_10_1074_jbc_M111_312959 crossref_primary_10_1038_srep40801 crossref_primary_10_1016_j_virol_2009_05_016 crossref_primary_10_1007_s00705_008_0214_7 crossref_primary_10_1128_JVI_02407_07 crossref_primary_10_1016_j_virol_2007_11_008 crossref_primary_10_1042_BST20140136 crossref_primary_10_1111_boc_201200006 crossref_primary_10_1073_pnas_1509745112 crossref_primary_10_3389_fmicb_2024_1422651 crossref_primary_10_1016_j_cell_2010_11_030 crossref_primary_10_1128_JVI_02606_10 crossref_primary_10_1128_JVI_00700_11 crossref_primary_10_3390_v13020233 crossref_primary_10_1016_j_biocel_2022_106185 crossref_primary_10_1371_journal_pone_0078074 crossref_primary_10_1073_pnas_1701747114 crossref_primary_10_1111_j_1462_5822_2010_01557_x crossref_primary_10_3390_v16020316 crossref_primary_10_1099_vir_0_046219_0 crossref_primary_10_1016_j_ejphar_2017_05_038 crossref_primary_10_12688_f1000research_8010_1 crossref_primary_10_1016_j_virusres_2015_01_010 crossref_primary_10_1080_22221751_2025_2558881 crossref_primary_10_1128_JVI_02215_16 crossref_primary_10_1016_j_virusres_2009_05_010 crossref_primary_10_1038_ncomms1647 crossref_primary_10_1016_j_virol_2010_06_030 crossref_primary_10_1128_JVI_00592_15 crossref_primary_10_1128_JVI_02150_16 crossref_primary_10_1099_jgv_0_000562 crossref_primary_10_1038_s41467_021_24724_2 crossref_primary_10_1038_ncomms14234 crossref_primary_10_1016_j_bpj_2013_03_054 crossref_primary_10_3390_ijms18010020 crossref_primary_10_1155_2011_245090 crossref_primary_10_1016_j_virusres_2011_02_006 crossref_primary_10_1128_JVI_01184_08 crossref_primary_10_1111_j_1462_5822_2012_01759_x crossref_primary_10_1007_s40588_016_0041_7 crossref_primary_10_1371_journal_ppat_1003413 crossref_primary_10_1016_j_antiviral_2008_04_006 crossref_primary_10_1128_JVI_01424_08 crossref_primary_10_1128_JVI_00534_09 crossref_primary_10_1128_JVI_01688_07 crossref_primary_10_1371_journal_pone_0165421 crossref_primary_10_3389_fimmu_2018_01581 crossref_primary_10_3390_pathogens8040168 crossref_primary_10_4049_jimmunol_1101823 crossref_primary_10_1128_JVI_06230_11 crossref_primary_10_1128_jvi_00716_22 crossref_primary_10_1016_j_bpj_2014_06_042 crossref_primary_10_1016_j_virol_2010_12_003 crossref_primary_10_1016_j_virol_2016_12_001 crossref_primary_10_1099_jgv_0_000535 crossref_primary_10_1016_j_vaccine_2009_12_079 crossref_primary_10_1080_14760584_2019_1704262 crossref_primary_10_1128_JVI_02188_10 crossref_primary_10_1128_JVI_00941_17 crossref_primary_10_1111_irv_12669 crossref_primary_10_1016_j_bbamem_2011_03_005 crossref_primary_10_1017_S1431927620000069 crossref_primary_10_4161_cib_16716 crossref_primary_10_1128_JVI_02240_09 crossref_primary_10_1016_j_virusres_2009_04_005 crossref_primary_10_1042_BCJ20160861 crossref_primary_10_1371_journal_pone_0094257 crossref_primary_10_1128_JVI_05970_11 crossref_primary_10_1016_j_vaccine_2016_04_089 crossref_primary_10_1016_j_bpj_2014_02_018 crossref_primary_10_1128_JVI_03123_12 crossref_primary_10_3390_v8090249 crossref_primary_10_1016_j_virusres_2010_07_006 crossref_primary_10_1128_JVI_06704_11 crossref_primary_10_1016_j_vaccine_2012_03_033 crossref_primary_10_1016_j_virusres_2009_12_010 crossref_primary_10_3390_v7122950 crossref_primary_10_1128_JVI_03306_14 crossref_primary_10_1128_jvi_00373_22 crossref_primary_10_1016_j_virol_2008_10_001 crossref_primary_10_1042_BST20120210 crossref_primary_10_1016_j_antiviral_2009_09_005 crossref_primary_10_1016_j_virusres_2012_08_014 crossref_primary_10_1080_07391102_2018_1436089 crossref_primary_10_1186_1743_422X_8_411 crossref_primary_10_1128_JVI_00947_17 crossref_primary_10_1016_j_cell_2010_08_029 crossref_primary_10_1016_j_jviromet_2010_02_009 crossref_primary_10_1128_JVI_00837_09 crossref_primary_10_1186_1743_422X_7_108 crossref_primary_10_1371_journal_ppat_1003067 crossref_primary_10_1128_JVI_01752_07 crossref_primary_10_1016_j_jviromet_2017_11_008 crossref_primary_10_1128_CMR_00097_12 crossref_primary_10_1128_JVI_00119_10 crossref_primary_10_1128_JVI_01322_10 crossref_primary_10_1111_irv_12472 crossref_primary_10_1016_j_virol_2010_09_022 crossref_primary_10_1074_jbc_M111_319996 crossref_primary_10_1016_j_vaccine_2018_02_106 crossref_primary_10_1016_j_vaccine_2015_07_023 crossref_primary_10_3390_vaccines10091520 crossref_primary_10_1073_pnas_1002123107 crossref_primary_10_1093_nar_gkz1094 crossref_primary_10_1016_j_chom_2014_03_002 crossref_primary_10_1016_j_jviromet_2008_07_015 crossref_primary_10_1016_j_jviromet_2008_10_020 crossref_primary_10_1128_JVI_01363_13 crossref_primary_10_1016_j_vaccine_2011_06_068 crossref_primary_10_1016_j_jbiotec_2016_06_029 crossref_primary_10_1038_nature07231 crossref_primary_10_1159_000346773 crossref_primary_10_1016_j_vaccine_2011_12_083 crossref_primary_10_1111_jfb_14571 crossref_primary_10_3390_s16070950 crossref_primary_10_1038_s41598_023_39096_4 crossref_primary_10_1371_journal_pcbi_1003034 crossref_primary_10_3390_v11010046 crossref_primary_10_1073_pnas_1114728109 crossref_primary_10_3390_v15091786 crossref_primary_10_1155_2011_370606 crossref_primary_10_1111_pbi_12963 crossref_primary_10_1186_1753_6561_5_S1_P66 crossref_primary_10_1016_j_virol_2011_05_006 crossref_primary_10_1016_j_procbio_2011_02_019 crossref_primary_10_3390_vetsci11020093 crossref_primary_10_1016_j_vaccine_2015_03_052 crossref_primary_10_1128_JVI_02306_09 crossref_primary_10_1042_BST0381397 crossref_primary_10_1128_JVI_02340_09 crossref_primary_10_1371_journal_ppat_1003701 crossref_primary_10_1128_JVI_00858_17 crossref_primary_10_1007_s11262_022_01904_w crossref_primary_10_3390_vaccines8010139 crossref_primary_10_1134_S0026893324700043
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1128/JVI.00361-07
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Biology
ExternalDocumentID	17475660
Genre	Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NIGMS NIH HHS grantid: T32 GM008061 – fundername: NIAID NIH HHS grantid: R37 AI20201 – fundername: NIGMS NIH HHS grantid: T32 GM008152 – fundername: NIAID NIH HHS grantid: R37 AI020201
GroupedDBID	--- -~X .55 .GJ 0R~ 18M 29L 2WC 39C 3O- 4.4 41~ 53G 5GY 5RE 5VS 6TJ 85S AAFWJ AAGFI AAYJJ ABPPZ ACGFO ACNCT ADBBV ADXHL AENEX AFFNX AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CGR CS3 CUY CVF D0S DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 MVM N9A NPM O9- OHT OK1 P2P RHI RNS RPM RSF TR2 UPT VH1 W2D W8F WH7 WOQ X7M Y6R YQT ZGI ZXP ~02 ~KM 7X8 AFPKN
ID	FETCH-LOGICAL-c470t-f2010d94fc71c987584379e6324a501f9160ef9aacda1918be17c28513a5b3742
IEDL.DBID	7X8
ISICitedReferencesCount	240
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000247404900034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0022-538X
IngestDate	Sun Nov 09 10:15:31 EST 2025 Mon Jul 21 06:04:11 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	13
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c470t-f2010d94fc71c987584379e6324a501f9160ef9aacda1918be17c28513a5b3742
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	http://doi.org/10.1128/JVI.00361-07
PMID	17475660
PQID	70613091
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_70613091 pubmed_primary_17475660
PublicationCentury	2000
PublicationDate	2007-07-01
PublicationDateYYYYMMDD	2007-07-01
PublicationDate_xml	– month: 07 year: 2007 text: 2007-07-01 day: 01
PublicationDecade	2000
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Journal of virology
PublicationTitleAlternate	J Virol
PublicationYear	2007
References	10423131 - J Gen Virol. 1999 Jul;80 ( Pt 7):1635-45 11831692 - Virology. 1995 Apr 1;208(1):121-31 15723524 - Biochemistry. 2005 Mar 1;44(8):2800-10 11451488 - Virus Res. 2001 Sep;77(1):61-9 10430945 - Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9345-50 7707543 - J Virol. 1995 May;69(5):3156-60 8764008 - J Virol. 1996 Aug;70(8):5016-24 10590147 - J Virol. 2000 Jan;74(1):547-51 11967285 - J Virol. 2002 May;76(10):4679-87 8551626 - J Virol. 1996 Feb;70(2):873-9 9427762 - EMBO J. 1998 Jan 2;17(1):288-96 16873274 - J Virol. 2006 Aug;80(16):8178-89 2455818 - J Virol. 1988 Aug;62(8):2762-72 7508993 - J Virol. 1994 Mar;68(3):1316-23 11773413 - J Virol. 2002 Feb;76(3):1391-9 10400805 - J Virol. 1999 Aug;73(8):7035-8 14990685 - J Virol. 2004 Mar;78(6):2657-65 15731254 - J Virol. 2005 Mar;79(6):3595-605 15709019 - J Virol. 2005 Mar;79(5):2988-97 15231380 - Virology. 2004 Jul 20;325(1):1-10 14505570 - Cell. 2003 Sep 19;114(6):701-13 10954572 - J Virol. 2000 Sep;74(18):8709-19 11312656 - Virology. 2001 Apr 25;283(1):1-6 11907235 - J Virol. 2002 Apr;76(8):3952-64 17005661 - J Virol. 2006 Dec;80(24):12070-8 11095724 - Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13871-6 15473846 - Annu Rev Cell Dev Biol. 2004;20:395-425 17005709 - J Virol. 2006 Oct;80(20):10289 12574509 - Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2002-7 16699003 - J Virol. 2006 Jun;80(11):5233-40 9670007 - EMBO J. 1998 Jul 15;17(14):3899-908 15298170 - Curr Top Microbiol Immunol. 2004;283:145-96 12490406 - Virology. 2002 Dec 5;304(1):89-96 9847327 - J Virol. 1999 Jan;73(1):242-50 1629953 - J Virol. 1992 Aug;66(8):4737-47 10559331 - J Virol. 1999 Dec;73(12):10158-63 11090151 - J Virol. 2000 Dec;74(24):11538-47 17146053 - Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19123-7 3095828 - Proc Natl Acad Sci U S A. 1986 Nov;83(21):8122-6 9135140 - EMBO J. 1997 Mar 17;16(6):1236-47 16227287 - J Virol. 2005 Nov;79(21):13673-84 9890962 - J Biol Chem. 1999 Jan 22;274(4):2038-44 16364736 - Virology. 2006 Jan 5;344(1):55-63 15113907 - J Virol. 2004 May;78(10):5258-69 16474138 - J Virol. 2006 Mar;80(5):2318-25 10753711 - Virology. 2000 Apr 10;269(2):325-34 10074141 - J Virol. 1999 Apr;73(4):2921-9 7957116 - EMBO J. 1994 Nov 15;13(22):5504-15 9780049 - J Gen Virol. 1998 Oct;79 ( Pt 10):2435-46 8411379 - J Virol. 1993 Nov;67(11):6762-7 11390617 - J Virol. 2001 Jul;75(13):6154-65 14561897 - Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14610-7 11013211 - EMBO J. 2000 Oct 2;19(19):5081-91 1660837 - Gene. 1991 Dec 15;108(2):193-9 16437116 - Nature. 2006 Jan 26;439(7075):490-2 10775599 - J Virol. 2000 May;74(10):4634-44 11595185 - Cell. 2001 Oct 5;107(1):55-65 9813197 - Virology. 1998 Nov 10;251(1):1-15 9576955 - Proc Natl Acad Sci U S A. 1998 May 12;95(10):5746-51 16139601 - Adv Virus Res. 2005;64:383-416 7483820 - Virus Res. 1995 Jun;37(1):37-47 10662624 - Virology. 2000 Feb 15;267(2):289-98 16249012 - Virology. 2005 Nov 25;342(2):215-27 16051827 - J Virol. 2005 Aug;79(16):10348-55 8794300 - J Virol. 1996 Oct;70(10):6653-7 10211954 - J Gen Virol. 1999 Apr;80 ( Pt 4):863-9
References_xml	– reference: 16249012 - Virology. 2005 Nov 25;342(2):215-27 – reference: 11773413 - J Virol. 2002 Feb;76(3):1391-9 – reference: 14505570 - Cell. 2003 Sep 19;114(6):701-13 – reference: 8551626 - J Virol. 1996 Feb;70(2):873-9 – reference: 10775599 - J Virol. 2000 May;74(10):4634-44 – reference: 9135140 - EMBO J. 1997 Mar 17;16(6):1236-47 – reference: 7483820 - Virus Res. 1995 Jun;37(1):37-47 – reference: 10753711 - Virology. 2000 Apr 10;269(2):325-34 – reference: 17146053 - Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19123-7 – reference: 15298170 - Curr Top Microbiol Immunol. 2004;283:145-96 – reference: 12574509 - Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2002-7 – reference: 9427762 - EMBO J. 1998 Jan 2;17(1):288-96 – reference: 9576955 - Proc Natl Acad Sci U S A. 1998 May 12;95(10):5746-51 – reference: 8764008 - J Virol. 1996 Aug;70(8):5016-24 – reference: 9847327 - J Virol. 1999 Jan;73(1):242-50 – reference: 9813197 - Virology. 1998 Nov 10;251(1):1-15 – reference: 1629953 - J Virol. 1992 Aug;66(8):4737-47 – reference: 11907235 - J Virol. 2002 Apr;76(8):3952-64 – reference: 1660837 - Gene. 1991 Dec 15;108(2):193-9 – reference: 8794300 - J Virol. 1996 Oct;70(10):6653-7 – reference: 15473846 - Annu Rev Cell Dev Biol. 2004;20:395-425 – reference: 14561897 - Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14610-7 – reference: 9780049 - J Gen Virol. 1998 Oct;79 ( Pt 10):2435-46 – reference: 7957116 - EMBO J. 1994 Nov 15;13(22):5504-15 – reference: 8411379 - J Virol. 1993 Nov;67(11):6762-7 – reference: 11013211 - EMBO J. 2000 Oct 2;19(19):5081-91 – reference: 3095828 - Proc Natl Acad Sci U S A. 1986 Nov;83(21):8122-6 – reference: 16873274 - J Virol. 2006 Aug;80(16):8178-89 – reference: 16437116 - Nature. 2006 Jan 26;439(7075):490-2 – reference: 16699003 - J Virol. 2006 Jun;80(11):5233-40 – reference: 17005709 - J Virol. 2006 Oct;80(20):10289 – reference: 10954572 - J Virol. 2000 Sep;74(18):8709-19 – reference: 11595185 - Cell. 2001 Oct 5;107(1):55-65 – reference: 7707543 - J Virol. 1995 May;69(5):3156-60 – reference: 10430945 - Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9345-50 – reference: 16474138 - J Virol. 2006 Mar;80(5):2318-25 – reference: 12490406 - Virology. 2002 Dec 5;304(1):89-96 – reference: 10400805 - J Virol. 1999 Aug;73(8):7035-8 – reference: 9670007 - EMBO J. 1998 Jul 15;17(14):3899-908 – reference: 11312656 - Virology. 2001 Apr 25;283(1):1-6 – reference: 11090151 - J Virol. 2000 Dec;74(24):11538-47 – reference: 11967285 - J Virol. 2002 May;76(10):4679-87 – reference: 15113907 - J Virol. 2004 May;78(10):5258-69 – reference: 15723524 - Biochemistry. 2005 Mar 1;44(8):2800-10 – reference: 16227287 - J Virol. 2005 Nov;79(21):13673-84 – reference: 15709019 - J Virol. 2005 Mar;79(5):2988-97 – reference: 15731254 - J Virol. 2005 Mar;79(6):3595-605 – reference: 10662624 - Virology. 2000 Feb 15;267(2):289-98 – reference: 9890962 - J Biol Chem. 1999 Jan 22;274(4):2038-44 – reference: 10559331 - J Virol. 1999 Dec;73(12):10158-63 – reference: 14990685 - J Virol. 2004 Mar;78(6):2657-65 – reference: 16364736 - Virology. 2006 Jan 5;344(1):55-63 – reference: 11095724 - Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13871-6 – reference: 10211954 - J Gen Virol. 1999 Apr;80 ( Pt 4):863-9 – reference: 10423131 - J Gen Virol. 1999 Jul;80 ( Pt 7):1635-45 – reference: 17005661 - J Virol. 2006 Dec;80(24):12070-8 – reference: 11390617 - J Virol. 2001 Jul;75(13):6154-65 – reference: 7508993 - J Virol. 1994 Mar;68(3):1316-23 – reference: 11831692 - Virology. 1995 Apr 1;208(1):121-31 – reference: 10074141 - J Virol. 1999 Apr;73(4):2921-9 – reference: 16139601 - Adv Virus Res. 2005;64:383-416 – reference: 10590147 - J Virol. 2000 Jan;74(1):547-51 – reference: 11451488 - Virus Res. 2001 Sep;77(1):61-9 – reference: 2455818 - J Virol. 1988 Aug;62(8):2762-72 – reference: 16051827 - J Virol. 2005 Aug;79(16):10348-55 – reference: 15231380 - Virology. 2004 Jul 20;325(1):1-10
SSID	ssj0014464
Score	2.3837419
Snippet	For influenza virus, we developed an efficient, noncytotoxic, plasmid-based virus-like particle (VLP) system to reflect authentic virus particles. This system...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	7111
SubjectTerms	Animals Cercopithecus aethiops COS Cells DNA-Directed RNA Polymerases Gene Expression HeLa Cells Hemagglutinin Glycoproteins, Influenza Virus - genetics Hemagglutinin Glycoproteins, Influenza Virus - metabolism Humans Influenza A Virus, H3N2 Subtype - physiology Influenza A Virus, H3N2 Subtype - ultrastructure Models, Biological Neuraminidase - genetics Neuraminidase - metabolism Plasmids - genetics Plasmids - metabolism Vaccinia virus Vero Cells Viral Matrix Proteins - genetics Viral Matrix Proteins - metabolism Viral Proteins Virus Assembly - physiology
Title	Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles
URI	https://www.ncbi.nlm.nih.gov/pubmed/17475660 https://www.proquest.com/docview/70613091
Volume	81
WOSCitedRecordID	wos000247404900034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTuQwELUYYCQubDPsSx044iHpTtqJhIQQAsFoaHEA1LeWY5dRBO00vQn4FL6WqqQjTiMOXHLKJqfs956r8kqIg2YjdKgdSpskKKPUKamDLJMGVQvRtEyYle76_1S7nXQ66c2MOK7_heGyynpNLBdqWxjeIz9SDDwEbif9Z8k9ozi3Om2g8UPMNYnIcEGX6nzmEEjoRLVXOE3rTl323kiO_t5f_WEnFlLS6v_UsoSYi6XvvdyyWJxSSzitYmFFzKBfFT-rZpOvv8T7VdWP5E3DJB-Mh8B2rQ8PHHk-96C9BTa31Gw2YgnbDiEbj8AXIyCOCD228n-B0tYh94egBwgD5DJitEDEF4iEYy97ei1vlI0tYyIUDvpEz3u5lZZCfULnls-WT_kjQr-uyvst7i7Ob88u5bQzgzSRCkbScQ7dppEzKjQpSZ6EbQ2Rrd91HISOOGeALtXaWE2CMMkwVKZB5K6p46xJanxNzPrC44aAVhLxqoCBjdIoTpH4UuwsIYh2ISqMN8V-PeRdinxOZ2iPxXjYrQd9U6xXX63brww6uqSyFNHUYOvLa7fFQr1ZG4Q7Ys7RnMddMW8mo3w42CsDio7tm-sP4BjZhw
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influenza+virus+hemagglutinin+and+neuraminidase%2C+but+not+the+matrix+protein%2C+are+required+for+assembly+and+budding+of+plasmid-derived+virus-like+particles&rft.jtitle=Journal+of+virology&rft.au=Chen%2C+Benjamin+J&rft.au=Leser%2C+George+P&rft.au=Morita%2C+Eiji&rft.au=Lamb%2C+Robert+A&rft.date=2007-07-01&rft.issn=0022-538X&rft.volume=81&rft.issue=13&rft.spage=7111&rft_id=info:doi/10.1128%2FJVI.00361-07&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon